Serena Nik-Zainal, MD, discusses study findings that could change the way treatment strategies for subgroups of patients with triple-negative breast cancer are evaluated.
Researchers report on the BRIGHT AML 1019 Phase III trial.
A new study looked at the characteristics of diagnosed breast cancer cases in San Francisco.
Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study.
Researchers explore the predictive capability of EVI1 expression.
CancerNetwork® spoke with Dr. Peter Schmid about the KEYNOTE-522 trial.
TAS-102 improved overall survival, compared with placebo, in patients with metastatic gastric or gastroesophageal junction (GEJ) cancer.
The results showed that even patients with disease that has spread to the brain should be considered for immunotherapy.
One-third of patients with locally advanced non-small cell lung cancer treated with durvalumab developed symptomatic pneumonitis.
The agent has a high affinity and specificity for interleukin-1 beta.
A study showed patients seem to lack an understanding of the meaning of progression-free survival.
Multigene testing for all woman diagnosed with breast cancer can be “extremely cost-effective.”
CancerNetwork® spoke with Dr. William Wood on the clinical risk of chemotherapy in early breast cancer.
How much do you know about the role of CAR T cells in multiple myeloma? Here's your chance to find out.
Metformin appeared to increase glucose uptake in lung cancer cells, according to results from a phase II trial.